Thrombin biosimilar - Leukocare / Navigo Proteins

Drug Profile

Thrombin biosimilar - Leukocare / Navigo Proteins

Alternative Names: recombinant human thrombin - Navigo Proteins/LEUKOCARE; rhThrombin - Navigo Proteins/LEUKOCARE

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEUKOCARE; Scil Proteins
  • Developer Navigo Proteins
  • Class Antifibrinolytics; Antihaemorrhagics; Blood coagulation factors; Coagulants; Serine endopeptidases
  • Mechanism of Action Thrombin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Haemorrhage

Highest Development Phases

  • Clinical Phase Unknown Haemorrhage

Most Recent Events

  • 15 Nov 2013 Thrombin biosimilar - Leukocare / Scil Proteins is available for licensing as of 30 Oct 2013.
  • 30 Oct 2013 Clinical trials in Haemorrhage in Germany (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top